CPX‐351 (Vyxeos(®)) can cause severe rash in acute myeloid leukemia—A case report

CPX‐351, a promising new agent for patients with treatment‐related and secondary acute myeloid leukemia can lead to a severe whole‐body rash. Although severe side effects are rare, treatment should be carefully monitored at specialized centers.

Gardado en:
Detalles Bibliográficos
Publicado en:Clin Case Rep
Main Authors: Urbantat, Ruth M., Popper, Valentin, Menschel, Elisabeth, Pfeilstöcker, Michael, Forjan, Ernst, Nader, Alexander, Sieghart, Catherine R., Keil, Felix, Koller, Elisabeth
Formato: Artigo
Idioma:Inglês
Publicado: John Wiley and Sons Inc. 2021
Assuntos:
Case Reports
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC8077323/
https://ncbi.nlm.nih.gov/pubmed/33936618
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ccr3.3909
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares